Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $45,849.00 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 53,940 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $0.85, for a total value of $45,849.00. Following the transaction, the director directly owned 2,105,920 shares of the company’s stock, valued at $1,790,032. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $69,650.76.

Werewolf Therapeutics Trading Up 0.5%

NASDAQ:HOWL opened at $0.72 on Friday. The stock has a 50 day moving average of $0.81 and a 200-day moving average of $0.89. The firm has a market capitalization of $35.14 million, a PE ratio of -0.53 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 52 week low of $0.53 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.14. As a group, analysts predict that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the period. Bank of America Corp DE increased its holdings in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after buying an additional 221,766 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics in the second quarter valued at $409,000. Finally, Citadel Advisors LLC bought a new position in shares of Werewolf Therapeutics in the third quarter valued at $304,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.